[HIV感染治疗研究进展]。

Kotaro Shirakawa
{"title":"[HIV感染治疗研究进展]。","authors":"Kotaro Shirakawa","doi":"10.11406/rinketsu.66.796","DOIUrl":null,"url":null,"abstract":"<p><p>Antiretroviral therapy (ART) is a well-established treatment for HIV infection that suppresses viral replication by inhibiting viral enzymatic activity, thereby preventing progression to immunodeficiency. However, discontinuation of ART typically leads to rapid viral rebound within weeks, due to the reactivation of latent HIV from long-lived reservoirs such as resting CD4<sup>+</sup> T cells. Eradication of these latent reservoirs is essential to achieve a cure for HIV. In 2009, the first case of HIV cure was reported: an individual with HIV and acute leukemia received an allogeneic hematopoietic stem cell transplant (HSCT) from a donor homozygous for the CCR5Δ32 mutation, which results in the absence of the HIV coreceptor CCR5. After ART interruption, the patient maintained undetectable plasma viremia without viral rebound. Since then, a total of nine cases with similar post-transplant virological remission have been documented globally. This review summarizes the clinical characteristics of reported cases of HIV cure, outlines the shock-and-kill strategy targeting latent HIV reservoirs, and discusses the current progress in the development of therapies to cure HIV using latency-reversing agents (LRAs).</p>","PeriodicalId":93844,"journal":{"name":"[Rinsho ketsueki] The Japanese journal of clinical hematology","volume":"66 8","pages":"796-805"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Recent advances in research of cure of HIV infection].\",\"authors\":\"Kotaro Shirakawa\",\"doi\":\"10.11406/rinketsu.66.796\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Antiretroviral therapy (ART) is a well-established treatment for HIV infection that suppresses viral replication by inhibiting viral enzymatic activity, thereby preventing progression to immunodeficiency. However, discontinuation of ART typically leads to rapid viral rebound within weeks, due to the reactivation of latent HIV from long-lived reservoirs such as resting CD4<sup>+</sup> T cells. Eradication of these latent reservoirs is essential to achieve a cure for HIV. In 2009, the first case of HIV cure was reported: an individual with HIV and acute leukemia received an allogeneic hematopoietic stem cell transplant (HSCT) from a donor homozygous for the CCR5Δ32 mutation, which results in the absence of the HIV coreceptor CCR5. After ART interruption, the patient maintained undetectable plasma viremia without viral rebound. Since then, a total of nine cases with similar post-transplant virological remission have been documented globally. This review summarizes the clinical characteristics of reported cases of HIV cure, outlines the shock-and-kill strategy targeting latent HIV reservoirs, and discusses the current progress in the development of therapies to cure HIV using latency-reversing agents (LRAs).</p>\",\"PeriodicalId\":93844,\"journal\":{\"name\":\"[Rinsho ketsueki] The Japanese journal of clinical hematology\",\"volume\":\"66 8\",\"pages\":\"796-805\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"[Rinsho ketsueki] The Japanese journal of clinical hematology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.11406/rinketsu.66.796\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"[Rinsho ketsueki] The Japanese journal of clinical hematology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.11406/rinketsu.66.796","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

抗逆转录病毒疗法(ART)是一种公认的HIV感染治疗方法,通过抑制病毒酶活性来抑制病毒复制,从而防止进展为免疫缺陷。然而,停止抗逆转录病毒治疗通常会导致病毒在数周内迅速反弹,这是由于潜伏的HIV从长期存在的储存库(如静止的CD4+ T细胞)重新激活。根除这些潜伏宿主对于治愈艾滋病毒至关重要。2009年,首例艾滋病毒治愈病例被报道:一名患有艾滋病毒和急性白血病的个体接受了来自供体CCR5Δ32突变纯合子的异体造血干细胞移植(HSCT),该突变导致艾滋病毒辅助受体CCR5缺失。中断抗逆转录病毒治疗后,患者维持未检测到的血浆病毒血症,无病毒反弹。从那时起,全球共有9例移植后类似病毒学缓解的病例被记录在案。本文综述了已报道的HIV治愈病例的临床特点,概述了针对潜伏HIV库的休克-杀伤策略,并讨论了目前使用潜伏逆转药物(LRAs)治愈HIV的治疗方法的进展。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
[Recent advances in research of cure of HIV infection].

Antiretroviral therapy (ART) is a well-established treatment for HIV infection that suppresses viral replication by inhibiting viral enzymatic activity, thereby preventing progression to immunodeficiency. However, discontinuation of ART typically leads to rapid viral rebound within weeks, due to the reactivation of latent HIV from long-lived reservoirs such as resting CD4+ T cells. Eradication of these latent reservoirs is essential to achieve a cure for HIV. In 2009, the first case of HIV cure was reported: an individual with HIV and acute leukemia received an allogeneic hematopoietic stem cell transplant (HSCT) from a donor homozygous for the CCR5Δ32 mutation, which results in the absence of the HIV coreceptor CCR5. After ART interruption, the patient maintained undetectable plasma viremia without viral rebound. Since then, a total of nine cases with similar post-transplant virological remission have been documented globally. This review summarizes the clinical characteristics of reported cases of HIV cure, outlines the shock-and-kill strategy targeting latent HIV reservoirs, and discusses the current progress in the development of therapies to cure HIV using latency-reversing agents (LRAs).

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信